Early-stage therapeutics company based in Cambridge, Massachusetts, incorporated in 2026
Raised to date
$470K
of $1M offered across 1 Form D filing
It describes itself as leveraging knowledge across multiple fields of biology to bring forward a new generation of treatments for a broad range of unmet medical needs. As of this research the company has disclosed no pipeline, platform, disease area or team publicly — its website is a single landing page with a contact form. Its first SEC Form D reports $470,000 sold to 7 investors against a $1,000,000 offering.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Mar 23, 2026 | Security to be acquired | $470K/ $1M | Form D |
Therapeutics
DNP Therapeutics has not publicly named any program, drug candidate, platform or disease indication. Its only public statement of what it is building is that it draws on multiple fields of biology to develop new treatments for unmet medical needs.